Omeros Strikes $2.1 Billion Deal, Granting Novo Nordisk Exclusive Global Rights to Zaltenibart
Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.
/ 932 items
#Healthcare↓
Wells Fargo Upgrades Apellis to Overweight - $32 Price Target
Wells Fargo raises Apellis to Overweight with $32 target, citing stable Syfovre sales and strong Empaveli launch potential. Stock could gain 15-20%.
Truist Initiates MBX Biosciences Coverage with $50 Price Target
Truist analyst sets Buy rating on MBX Biosciences with $50 target, citing strong potential for lead drug canvuparatide (MBX 2109) with projected $3.2B peak sales by 2036.
Halozyme Gets Upgrade as Medicare Impact Fears Ease
Leerink upgrades Halozyme to Market Perform after company reveals only 20% of ENHANZE sales come from Medicare Part B, significantly less than feared. Price target remains $70.
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
Senti Biosciences Gets Bullish Analyst Coverage with 614% Upside Potential
H.C. Wainwright initiates Senti Bio with Buy rating and $12 target. Cancer therapy developer's CAR-NK platform shows promise for blood cancers and solid tumors.